Chronic kidney disease (CKD) remains a growing problem in the United
States. In 2000, an estimated 400,000 U.S. patients received either a
kidney transplant or dialysis.1 This number is expected to
rise to 2 million by 2030. Osteoporosis is another concern, with the
incidence in individuals aged over 50 years ranging from 6% in men to
7.2% in women.2,3
Bisphosphonates, which are excreted via the kidneys, may accumulate
in patients with diminished renal function, and toxicity may occur.
There have been several reports of acute renal toxicity following
bisphosphonate treatment. Seven bisphosphonates are approved for use in
the U.S.,